Question 2 - Antiretroviral Medications and Initial Therapy Question Bank

Antiretroviral Therapy.

Available Topics

1. Screening and Diagnosis3rd Edition

2. Basic HIV Primary Care3rd Edition

3. Antiretroviral Therapy3rd Edition

4. Co-Occurring Conditions3rd Edition

5. Prevention of HIV3rd Edition

6. Key Populations3rd Edition

Antiretroviral Medications and Initial TherapyQuestion 2/10

A 31-year-old cisgender man is seen in clinic to discuss starting antiretroviral therapy. He was recently diagnosed with HIV, and initial laboratory studies showed a CD4 count of 470 cells/mm³ and an HIV RNA of 75,680 copies/mL. A baseline HIV drug resistance genotype assay was ordered and the result is pending. He has never taken HIV preexposure prophylaxis (PrEP).

According to the Adult and Adolescent ART Guidelines, which one of the following would be considered a recommended initial antiretroviral regimen for this patient?

Rilpivirine-tenofovir alafenamide-emtricitabine

Doravirine-tenofovir DF-lamivudine

Bictegravir-tenofovir alafenamide-emtricitabine

Darunavir-cobicistat-tenofovir alafenamide-emtricitabine

Provide Question Feedback

Previous Question Skip Question

Prev Skip

Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.

Question Last Updated
October 8th, 2024

Table 1. **Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV**

Recommended Initial Regimens for Most People with HIV
Recommended regimens are those with demonstrated durable virologic efficacy, favorable tolerability and toxicity profiles, and ease of use. Choice of antiretroviral therapy during pregnancy should be guided by recommendations from the Perinatal Guidelines.
For people who do NOT have a history of long-acting cabotegravir use as HIV PrEP, the following regimens are recommended:
INSTI + 2 NRTIs: Bictegravir-tenofovir alafenamide-emtricitabine (AI) Dolutegravir plus (tenofovir alafenamide or tenofovir DF)^a plus (emtricitabine or lamivudine) (AI) INSTI + 1 NRTI Dolutegravir-lamivudine (AI)—except for individuals with HIV RNA >500,000 copies/mL, HBV coinfection, or when antiretroviral therapy is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available
For people with HIV and a history of using long-acting cabotegravir as HIV PrEP, integrase genotypic drug resistance testing should be done before the start of antiretroviral therapy. If treatment is begun prior to the results of genotypic testing, the following regimen is recommended:
Boosted PI + 2 NRTIs: Darunavir (boosted with cobicistat or ritonavir) plus (tenofovir alafenamide or tenofovir DF)^a plus (emtricitabine or lamivudine)—pending the results of the genotype test (AIII).
Abbreviations: INSTI = integrase strand transfer inhibitor; NRTI = nucleoside reverse transcriptase inhibitor ^aTenofovir alafenamide and tenofovir DF are two forms of tenofovir approved by the FDA. Tenofovir alafenamide has fewer bone and kidney toxicities than tenofovir DF, whereas tenofovir DF is associated with lower lipid levels. Safety, cost, and access are among the factors to consider when choosing between these drugs. Rating of Recommendations: A = Strong; B = Moderate; C = Weak Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies, or regimen comparisons from randomized switch studies; III = Expert opinion

Source:

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. What to start: initial combination regimens for people with HIV. September 12, 2024. [HIV.gov]

Steps to Acquire CE for this Question Bank Topic:

Answer

Answer all questions

Score 80%+

Answer correctly

Claim CE

Choose CNE or CME

Give Feedback

Complete survey

Print Certificate

Obtain proof of CE

Single-Tablet Regimens

Long-Acting Injectable Regimens

Capsid Inhibitors

Entry Inhibitors

Integrase Inhibitors (INSTI)

Nucleoside Reverse Transcriptase Inhibitors (NRTI)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)

Protease Inhibitors (PI)

Pharmacokinetic Enhancers

Self-Study Module3rd EditionCNE/CME Available

Lessons

Quick Reference3rd Edition

Lessons

Self-Study Module3rd EditionCNE/CME Available

Lessons

Quick Reference3rd Edition

Lessons

Self-Study Module3rd EditionCNE/CME Available

Lessons

Quick Reference3rd Edition

Lessons

Self-Study Module3rd EditionCNE/CME Available

Lessons

Quick Reference3rd Edition

Lessons

Self-Study Module3rd EditionCNE/CME Available

Lessons

Quick Reference3rd Edition

Lessons

Self-Study Module3rd EditionCNE/CME Available

Lessons

Quick Reference3rd Edition

Lessons

Antiretroviral Therapy.

Available Topics

Progress Tracker

HIV Question Bank

Antiretroviral Medications and Initial TherapyQuestion 2/10

Questions in Topic

According to the Adult and Adolescent ART Guidelines, which one of the following would be considered a recommended initial antiretroviral regimen for this patient?

Recommended Initial Regimens for Most People with HIV

Steps to Acquire CE for this Question Bank Topic:

Sign In

Answer

Score 80%+

Claim CE

Give Feedback

Print Certificate